Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.
Pfizer steps into in vivo CAR T space with $2.6B licensing deal
On Wednesday, Pfizer announced an exclusive licensing deal with Starna Therapeutics, giving Pfizer the rights to three in vivo pre-IND CAR-T autoimmune programs. Under the agreement, Starna will receive an upfront payment of $330 million, with the potential to earn up to $2.3 billion in milestone payments and royalties on net sales of any approved products. The deal comes amidst a flood of patents that will expire for Pfizer in the next few years, and marks Pfizer’s first foray into the in vivo CAR-T space. “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches,” said Michael Vincent, Chief Inflammation & Immunology Officer at Pfizer, in the press release. – Allison Whitten
First FDA-approved treatment for primary membranous nephropathy
Genentech’s Gazyva (obinutuzumab) has become the first FDA-approved treatment for primary membranous nephropathy (pMN), a rare autoimmune disease that damages the kidneys and can lead to kidney failure. The approval is based on the Phase 3 MAJESTY trial, in which 36.1 percent of patients receiving Gazyva achieved complete remission of proteinuria after two years, compared with 5.7 percent of those treated with the immunosuppressant tacrolimus. Proteinuria, or excess protein in the urine, is a key indicator of kidney damage in people with pMN. Gazyva is an anti-CD20 antibody that targets B cells, which play a role in the autoimmune response underlying the disease. The drug’s latest approval adds to its growing use in immune-mediated conditions, following FDA clearances for lupus nephritis and idiopathic nephrotic syndrome, alongside its existing cancer indications. – Bree Foster
Biogen’s early Alzheimer’s drug sees increasing improvements out to two years
This week at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, Biogen presented data showing that their tau-targeting antisense oligonucleotide continues to slow clinical decline across five of six measures at two years compared to 18 months. The data held at all doses studied, but the team noted that the 60mg dose showed the largest treatment effects and best benefit-risk profile. Biogen also reported biomarker findings from the Phase 2 open label CELIA study demonstrating that the drug reduced tau on PET scans of the brain. “These are highly encouraging results, particularly given the progressive nature of Alzheimer's disease,” said Lawren VandeVrede, a principal investigator in the Phase 2 CELIA study at the University of California, San Francisco, in the press release. “The increasing separation observed between 18 months and two years is remarkable and clinically meaningful. For patients and families, slowing clinical decline means more time in early stages, preserving independence, and remaining connected to the people and experiences that matter most. – Allison Whitten
FDA approves first drug for neurological Gaucher disease symptoms
For people living with Type 3 Gaucher disease (GD3), treatment has long been able to address the effects on the body while the disease kept progressing in the brain. This week, the FDA approved Sanofi's venglustat (Infilbray), the first therapy for the neurological manifestations of GD3, a rare inherited lysosomal storage disorder in which glycosphingolipids accumulate in the central nervous system and drive neuroinflammation. People with GD3 can experience cognitive decline, impaired balance and coordination, and seizures, often after a years-long path to diagnosis. Enzyme replacement therapy (ERT) treats the disease's systemic effects but cannot reach the brain, while venglustat, a once-daily oral glucosylceramide synthase inhibitor, is designed to cross the blood-brain barrier and reduce glycosphingolipid buildup. In the Phase 3 LEAP2MONO trial, 43 patients previously stabilized on ERT were randomized to venglustat or the ERT imiglucerase, and venglustat outperformed ERT on a combined measure of motor coordination and cognition at 52 weeks. For drug developers, the approval shows that a brain-penetrant small molecule can reach central nervous system pathology that large enzyme therapies cannot, a strategy relevant across other neuronopathic lysosomal storage disorders. It also sets a regulatory precedent: the FDA accepted a small, active-comparator trial built around a prespecified global test of motor and cognitive endpoints, a design that could guide pivotal studies in rare neurological diseases where small patient populations make single-endpoint trials hard to power. — Andrea Corona
Dicot Pharma advances erectile dysfunction drug into Phase 2b
Dicot Pharma has begun a Phase 2b trial of its erectile dysfunction drug candidate LIB-01 in the US, with approval to expand the study into Europe now also in place. The adaptive study will evaluate the effects of repeated monthly dosing across at least 200 participants with varying severities of erectile dysfunction, and aims to identify an appropriate dose for Phase 3 development. The trial will test 25mg and 50mg doses, which showed proof-of-concept in an earlier Phase 2a study, alongside a higher dose to be determined during the first part of the trial. Its primary endpoint is the change from baseline in International Index of Erectile Function erectile function (IIEF-EF) score at week 12. The first part of the study, which will establish the highest dose for the efficacy evaluation, is expected to finish in the first quarter of 2027. The second part will then assess efficacy, with sites planned in the US, France, the Netherlands, and Sweden. Sweden is the first EU country to approve the study. – Bree Foster








